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Investing in Sickness Rather Than Health
Dana P. Goldman, PhD, Étienne Gaudette, PhD, Wei-Han Cheng, MSIntroductionFighting disease is deeply ingrained in Americanmedical culture. The steadfast support for medicalresearch—fewer than one in ten Americans would
cut research to reduce the deﬁcit1—underpins a national
belief that curing cancer and other major diseases today
will mean longer, healthier lives tomorrow.
During the last half century, faith in the disease-
speciﬁc research model has rewarded the U.S. with
signiﬁcant returns on investment in life expectancy and
better health. But, there are troubling signs that targeting
diseases in isolation may be outliving its usefulness.
Prevalence of major chronic conditions—high blood
pressure, heart disease, diabetes, cancer, and stroke—is
increasing.2–4 This trend is fueled by a combination of
higher rates of obesity and gains in life expectancy, which
in turn will be driven by innovations in medical
technology that allow people to live longer with chronic
conditions.5
As a result, disability rates also are increasing,
suggesting the average length of a healthy life span—
deﬁned as length of life lived without disability—may
decrease in the future. For example, the authors
estimate that life expectancy for 65-year-olds will grow
by about a year between 2010 and 2030 to 20.1 years,
but expected years of life with a disability for 65-year-
olds during the same time will rise even more, from 7.4
years to 8.6 years.5
Likewise, disability rates have increased for younger
Americans, especially 30- to 49-year-olds, which could
have adverse consequences for public ﬁnancing of dis-
ability insurance, Medicare, and Medicaid.6 And though
attacking diseases individually has extended life for
younger and middle-aged people, competing risks from
other illnesses make such progress more difﬁcult for
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As people age, they are at less risk of falling victim to a
single isolated disease. Instead, competing causes of
death more directly associated with biological aging—
for example, heart disease, cancer, stroke, and Alzheimer
disease—cluster within individuals as they reach older
ages. These conditions elevate mortality risk and create
the frailty and disabilities that accompany old age.8
Nonetheless, most of the U.S. medical research and
healthcare delivery system remains focused solely on
speciﬁc, acute, episodic illnesses. The best metaphor is
NIH, which divides its budget among its major institutes
by focus on a particular disease or body system. As
Americans age, such strategies will yield diminishing
returns, because success in areas like heart disease may
mean more time lived with cancer, dementia, and
disability. This does not imply the disease model is a
failure. Rather, Americans are victims of their own
success, as they face a future where they live longer with
more disease and quality of life impairments.9
The point is that the model must change. Continuing
the same path of disease-speciﬁc biomedical innovation
seems likely to lead to a destination where research
investments increasingly will yield more sickness and
disability and less health. At the same time, recent
scientiﬁc advances suggest a new research course for
consideration: slowing the aging process itself—known as
senescence—to extend healthy life spans and compress
sickness and disability toward the end of life.
What a Drag It Is Getting Old…
Aging is a major risk factor for most of the chronic
conditions—heart disease, cancer, and diabetes, for
example—that curtail longevity, self-sufﬁciency, and
health. And, these conditions will become progressively
more widespread as the elderly population grows. As
discussed earlier, treating chronic diseases in isolation is
a losing proposition. New research ﬁndings suggest that
aging itself is a modiﬁable risk factor: that it may be
possible to moderate the aging process to delay onset of
diseases associated with aging.
One possible mechanism is to target cellular senes-
cence to delay or prevent multiple age-related chronic
diseases as a group, rather than one at a time; somevier Inc. This is an
mmons.org/licenses/by-nc-nd/4.0/).
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cellular senescence into clinical treatments could trans-
form health care.10 The aging ﬁeld already is successfully
experimenting with interventions to delay aging in
animals. At the same time, new pharmacologic inter-
ventions with the potential to extend healthy life spans
and promote resilience in experimental animals are being
tested, including rapamycin, JAK1/2 inhibitors,
senescence-associated secretory phenotype, and protein
aggregation inhibitors.11
What this means is that just as the disease model is
showing diminishing returns, researchers are starting to
make progress in the biology of aging. There are
tremendous opportunities for research on the genetics
of human aging, particularly given the huge trove of
information on human biology and pathobiology and the
rapidly developing knowledge of the human genome.12Delayed Aging: Not Just Science Fiction
One can often see the potential of a new medical
technology by looking at what the private sector is doing.
The who’s who of the technology intelligentsia—Larry
Page of Google, Arthur Levinson of Apple, J. Craig
Venter of Human Longevity, Inc., Larry Ellis of Oracle, to
name a few—are investing serious money, hundreds of
millions of dollars, to advance promising research to
delay aging. And some of that research has moved
beyond the realm of science ﬁction into reality.
Scientists are extending the healthy life span of
invertebrates and mammals by manipulating genes,
altering reproduction, modulating the levels of hormones
that affect growth and maturation, and altering insulin
signaling pathways. Although many of these interven-
tions are unlikely to be directly applicable in humans,
they may lead scientiﬁc inquiry toward effective ways to
delay aging in people.
For example, reduced signaling of insulin-like peptides
was proven to increase the life span of mammals.13 Other
researchers have concluded that the offspring of parents
with exceptional longevity have a lower rate of dementia
than offspring of parents with usual survival, opening a
promising investigative path into whether genetic factors
associated with longevity may protect against dementia
and Alzheimer disease.14
Most centenarians appear to handle chronic diseases
better than others, averting disability until well into their
90s. Several studies have shown that centenarians have
many disease-associated protective genomic compo-
nents, suggesting an important role for protective var-
iants that can possibly slow the rate of aging and decrease
the risk of age-related diseases. Such genetic models mayaid in discovering new target genes and pathways related
to aging and longevity.15Economic and Health Dividends of Delayed
Aging
To illustrate the potential impact of innovation to delay
aging, simulations are conducted with the Future
Elderly Model (FEM), an established economic–demo-
graphic microsimulation that has been used to study a
wide variety of health policy questions with support
from NIH, the Centers for Medicare and Medicaid
Services, the MacArthur Foundation, and the Depart-
ment of Labor.16–19 The FEM follows the evolution of
individual-level health trajectories and economic out-
comes, rather than the average or aggregate character-
istics of a cohort. This enables assessment of how
lifetime health outcomes will change as underlying
relationships among disease, disability, and spending
are manipulated.
A “delayed aging” scenario that assumes successes
with animal models are translated into humans was
implemented. In other words, all age-related chronic
diseases and disability are delayed simultaneously as a
group instead of delaying single diseases one at a time.
Speciﬁcally, the scenario modiﬁes the health transitions
of the FEM to reduce the probability of onset of heart
disease, cancer, stroke or transient ischemic attack,
diabetes, chronic bronchitis and emphysema, hyper-
tension, all-cause mortality, and disability. This proba-
bility reduction is phased in gradually until the full
reduction is achieved in 2030.
Lifetime health and spending with these modiﬁed
health transition parameters and measured outcomes
were then simulated at the individual and population
levels. This optimistic but plausible scenario implies that
scientists could translate research on the biology of aging
into therapeutic interventions to extend human longevity
and compress disease and disability into a shorter period
at the end of life. Such a scenario has been explored in
more detail in previous work,20 and more detail about its
assumptions can be found in the Appendix (available
online).
Compared with the status quo scenario—leaving
current disease incidence and mortality trends
unchanged—the delayed aging scenario results in tre-
mendous gains in healthy life spans, slightly lower per
capita medical spending, and only modest overall
increases in total medical spending in 2030 (Table 1).
For example, under the delayed aging scenario, aver-
age life expectancy for 51-year-olds would increase 7.1
years more than under the status quo, from 32.5 years towww.ajpmonline.org
Table 1. Health Indicators and Medical Spending Estimates for the Population Aged 51 and Older in 2030 in Various
Scenarios
Status quo
Difference with status quo
Variable Delayed aging Exercise intervention
Life expectancy at age 51 32.5 7.1 0.7
Nondisabled 20.9 6.4 1.7
Disabled 11.6 0.7 –1.0
Total population (millions) 128 134 129
Average age 68.2 1.0 0.1
Chronic disease and disability prevalence (%)
Heart disease 30.7 –1.0 –1.3
Stroke 11.9 –0.4 –1.1
Diabetes 32.9 –1.7 –1.1
Disabled 27.8 –6.2 –3.8
Living in a nursing home 2.8 –0.2 –0.1
Per capita medical spending ($2014 thousands)
Medicare 11.7 –0.9 –0.3
Medicaid 3.3 0.0 –0.2
Total spending 26.8 –0.9 –0.6
Population medical spending ($2014 billions)
Medicare 1,494 –42 –32
Medicaid 419 22 –19
Total spending 3,431 59 –51
Note: The ﬁrst column of the table presents health indicators and medical spending projected by the Future Elderly Model’s baseline scenario in year
2030. The last two columns present differences in these outcomes between two alternative scenarios, the Delayed Aging and Exercise Intervention
scenarios, and the baseline projections. Disabled is deﬁned as having one or more limitations in instrumental activities of daily living, having one or
more limitations in activities of daily living, living in a nursing home, or a combination of the three.
Figure 1. Millions of non-disabled Americans aged 51 and
older in various scenarios, 2014–2050.
Note: The ﬁgure shows the number of Americans aged 51 years or older
projected to be not disabled according to the various scenarios.
Disabled is deﬁned as having one or more limitations in instrumental
activities of daily living, having one or more limitations in activities of
daily living, living in a nursing home, or a combination of the three.
Goldman et al / Am J Prev Med 2016;50(5S1):S45–S50 S47almost 40 years. Similarly, the share of the disabled
population aged 51 years and older would decline more
than 6 percentage points to about 22%, down from about
28% under the status quo.
Looked at another way, the number of nondisabled
Americans aged 51 years and older in 2030 would
increase by more than 23 million people under the
delayed aging scenario, from about 83 million people in
2014 to about 106 million in 2030 (Figure 1). By 2030,
there would be 13 million more nondisabled Americans
in the delayed aging scenario than the status quo.
Looking further ahead, the FEM projects that this
difference would reach 25 million people by 2050.
On the medical spending side, despite producing a
higher average age, the delayed aging scenario would
actually decrease per capita medical spending slightly by
about $900 (in 2014 dollars) in 2030 from the status quoMay 2016
Goldman et al / Am J Prev Med 2016;50(5S1):S45–S50S48projection of $26,800 annually, whereas population
medical spending would increase by about $59 billion
from the status quo estimate of $3.43 trillion.
Turning Delayed Aging Into Reality Would
Take Time
As is always the case with scientiﬁc advances, the
trajectory of biomedical innovation to delay aging, even
if embraced fully by policymakers and researchers, would
be uncertain and uneven. The delayed aging scenario,
though based on informed and grounded predictions,
provides an optimistic example of possible outcomes
from shifting the focus of biomedical research from
speciﬁc, individual diseases to unraveling, understanding,
and, ultimately, delaying the aging process.
And, as the possibilities of delayed aging are explored
and pursued as a bold prevention strategy, one shouldn’t
lose sight of existing low-tech but effective prevention
activities that could produce meaningful and almost
certain health and economic gains for Americans. In
the near term, one of the best investments Americans can
make to live longer, healthier lives is as low-tech as it gets
—regular physical aerobic and muscle-strengthening
activity—otherwise known as exercise!Exercise Is an Anti-aging Intervention
Compared with what is medically recommended and
compared with the rest of the world, Americans simply
don’t exercise enough. Only about one in ﬁve Americans
aged 18 years and older in 2013 met physical activity
guidelines for both aerobic and muscle-strengthening
activity, according to the Centers for Disease Control and
Prevention (CDC).21 And, based on 2011 WHO data,
41% of Americans aged 15 years and older were
considered “inactive”—a relatively high level compared
with other developed countries like Germany (28%),
France (32.5%), and Canada (33.9%).22
The lack of exercise in the U.S. has serious individual
and population health consequences and economic
burden. For example, research23 shows that a lower level
of cardiorespiratory ﬁtness has an inverse impact on
health beneﬁt and is signiﬁcantly associated with higher
risk of all-cause mortality and coronary heart disease/
cardiovascular disease in healthy men and women.
Compared with participants with high cardiorespiratory
ﬁtness, those with low cardiorespiratory ﬁtness had
higher rates of mortality and coronary heart disease/
cardiovascular disease events—up to 1.7-times higher
mortality rate and 1.6-times higher rate in coronary heart
disease/cardiovascular disease events.23Other research24 indicates that physical inactivity in
the U.S. is responsible for about 7% of the burden of
disease from coronary heart disease, 8% of Type 2
diabetes, and 12% of both breast cancer and colon
cancer. Moreover, the tremendous health beneﬁts of
exercise only increase as people become more active.
The American guidelines for physical activity reﬂect the
dose–response relationship concept between volume of
completed physical activity and exercise and achieved
health beneﬁts, advising that health beneﬁts are gained
with 150 minutes a week of mild to moderate physical
activity but that more health beneﬁts accrue with 300
minutes a week of moderate physical activity. All adults
—regardless of age, race, ethnicity, and weight—beneﬁt
from exercise and have lower rates of early death and
chronic diseases when they are physically active.25
Similar to the delayed aging scenario, an exercise
scenario was implemented in the FEM to illustrate the
impact of increasing physical activity and the beneﬁts to
U.S. population health through reduced risk of chronic
diseases and improved physical health status. To imple-
ment the exercise scenario, nondisabled individuals aged
51 years or older who are most likely to hardly ever or
never take part in sports or vigorous physical activities
were ﬁrst identiﬁed in the FEM simulation.
In 2014, this corresponds to 43 million people. The
scenario then made them exercise; that is, health transition
probabilities were altered to provide themwith the beneﬁts
of moderate to vigorous exercise identiﬁed by large RCTs
and observational studies.26–28 The simulation proceeded
similarly for each year, in effect providing low-exercising
Americans with the life-time beneﬁts of vigorous exercise.
A full review of this scenario and the literature consulted
are provided in the Appendix (available online).
As shown in Table 1 and Figure 1, the health and
economic beneﬁts of an exercise intervention, although
not as great as in the delayed aging scenario, are
substantial. For example, when comparing the exercise
scenario with the status quo, the number of nondisabled
people aged 51 years and older in 2030 would be higher
by about 5.7 million, and both per capita and overall total
medical spending would decline modestly.
Implications
Despite growing evidence that the disease-speciﬁc model
of biomedical innovation is reaching its limits, shifting
the nation’s real and intellectual capital to a delayed aging
focus will be no minor task. There are strong vested
interests in the current model. With some notable
exceptions,29 the U.S. insurance model is not designed
to pay for preventive services—like walks—that might
keep people healthy, but rather for treatments when theywww.ajpmonline.org
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ately argued that current life expectancy is long enough: an
ironic position given one could have made such an argu-
ment when life expectancy was 50 years, not 80 years.
But, the time has come for the U.S. to distance itself
from the rhetoric and colored ribbons of conquering
individual diseases to begin a real discussion about how
best to help Americans achieve longer, healthier, and
more productive lives. In the meantime, a brisk, daily, 45-
minute walk for about 43 million Americans wouldn’t
hurt.Publication of this article was supported by the Centers for
Disease Control and Prevention.
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